Literature DB >> 28360424

The emerging safety profile of JAK inhibitors in rheumatic disease.

Kevin L Winthrop.   

Abstract

Entities:  

Year:  2017        PMID： 28360424     DOI： 10.1038/nrrheum.2017.51

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  28 in total

Review 1.  Pemphigus: a Comprehensive Review on Pathogenesis, Clinical Presentation and Novel Therapeutic Approaches.

Authors:  Robert Pollmann; Thomas Schmidt; Rüdiger Eming; Michael Hertl
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 8.667

2.  Inhibition of JAK-STAT Signaling Suppresses Pathogenic Immune Responses in Medium and Large Vessel Vasculitis.

Authors:  Hui Zhang; Ryu Watanabe; Gerald J Berry; Lu Tian; Jörg J Goronzy; Cornelia M Weyand
Journal:  Circulation       Date:  2017-12-18       Impact factor: 29.690

3.  Immunosuppression in Rheumatologic and Auto-immune Disease.

Authors:  Arundathi Jayatilleke
Journal:  Handb Exp Pharmacol       Date:  2022

4.  Bioactive Compounds from Nyctanthes arbor tristis Linn as Potential Inhibitors of Janus Kinases (JAKs) Involved in Rheumatoid Arthritis.

Authors:  Love Edet Mendie; S Hemalatha
Journal:  Appl Biochem Biotechnol       Date:  2022-09-09       Impact factor: 3.094

Review 5.  Interleukin-6: designing specific therapeutics for a complex cytokine.

Authors:  Christoph Garbers; Sylvia Heink; Thomas Korn; Stefan Rose-John
Journal:  Nat Rev Drug Discov       Date:  2018-05-04       Impact factor: 84.694

Review 6.  Bedside to bench: defining the immunopathogenesis of psoriatic arthritis.

Authors:  Arlene Bravo; Arthur Kavanaugh
Journal:  Nat Rev Rheumatol       Date:  2019-09-04       Impact factor: 20.543

Review 7.  JAK out of the Box; The Rationale behind Janus Kinase Inhibitors in the COVID-19 setting, and their potential in obese and diabetic populations.

Authors:  Rahma Menshawey; Esraa Menshawey; Ayman H K Alserr; Antoine Fakhry Abdelmassih
Journal:  Cardiovasc Endocrinol Metab       Date:  2020-10-15

8.  Disruption of FOXP3-EZH2 Interaction Represents a Pathobiological Mechanism in Intestinal Inflammation.

Authors:  Adebowale O Bamidele; Phyllis A Svingen; Mary R Sagstetter; Olga F Sarmento; Michelle Gonzalez; Manuel B Braga Neto; Subra Kugathasan; Gwen Lomberk; Raul A Urrutia; William A Faubion
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2018-09-14

9.  Discovery of a highly selective JAK3 inhibitor for the treatment of rheumatoid arthritis.

Authors:  Heying Pei; Linhong He; Mingfeng Shao; Zhuang Yang; Yan Ran; Dan Li; Yuanyuan Zhou; Minghai Tang; Taijin Wang; Yanqiu Gong; Xiaoxin Chen; Shengyong Yang; Mingli Xiang; Lijuan Chen
Journal:  Sci Rep       Date:  2018-03-27       Impact factor: 4.379

Review 10.  Targeting the Immune System for Pulmonary Inflammation and Cardiovascular Complications in COVID-19 Patients.

Authors:  Serena Colafrancesco; Rossana Scrivo; Cristiana Barbati; Fabrizio Conti; Roberta Priori
Journal:  Front Immunol       Date:  2020-06-23       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.